Monday, 22 June 2026
PERSPECTA
News from every angle
All
Stream
World
Politics
Business
Technology
Finance
Science
Health
Culture
Opinion
Environment
← Back to headlines
Puma anticipates $194M–$198M NERLYNX revenue for 2026 while advancing alisertib clinical programs
27 Feb, 02:38 — 27 Feb, 02:38
Post
Share
Copy link
Embed
Sources
Sort: Relevance
Sort: Latest
Sort: Bias (L→R)
Sort: Bias (R→L)
Sort: Factuality
left
center
right
Showing 1 of 1 sources
seeking-alpha
Mixed
115d ago
Puma anticipates $194M–$198M NERLYNX revenue for 2026 while advancing alisertib clinical programs
Read full article →
Something wrong with this story? Report an issue
Related Stories
Amazon's First Customer Receipt Goes Viral, Bezos and Musk React
just now
Philippines Grapples with Plastic Waste Leakage Despite Existing Laws
just now
Visayas Sugar Farms Face Insect Infestation, Prompting Emergency Meeting
just now
UVision Plans Nasdaq IPO
just now
Monday, 22 June 2026
Explore
Log in
Sign up
en
PERSPECTA
News from every angle
